Table 2.
Needs for rehabilitation during 14 months following time of diagnosis
| Physical area | Emotional area | Family oriented area | Sexual area | Work-related area | Financial area | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n = 3,242 | n = 3,254 | n = 3,250 | n = 3,197 | n = 1,276 | n = 1,895 | ||||||||||||||
| n (%) | ORcrude | ORadja (95% CI) | n (%) | ORcrude | ORadja (95% CI) | n (%) | ORcrude | ORadja (95% CI) | n (%) | ORcrude | Men n = 1,366 ORadjb (95% CI) | Women n = 1,829 ORadjb (95% CI) | n (%) | ORcrude | ORadja (95% CI) | n (%) | ORcrude | ORadja (95% CI) | |
| Needs, total | 1,028 (31.7) | − | − | 997 (30.6) | − | − | 453 (13.9) | − | − | 529 (16.6) | − | − | − | 252 (19.8) | − | − | 257 (13.4) | − | − |
| Sex | |||||||||||||||||||
| Men | 352 (25.4) | 1.00 | 1.00 | 327 (23.5) | 1.00 | 1.00 | 145 (10.4) | 1.00 | 1.00 | 308 (22.5) | 1.00 | − | − | 77 (14.3) | 1.00 | 1.00 | 118 (13.8) | 1.00 | 1.00 |
| Women | 676 (36.5) | 1.69** | 1.36** (1.01–1.70) | 670 (35.9) | 1.82** | 1.72** (1.37–2.17) | 308 (16.6) | 1.70** | 1.40* (1.04–1.88) | 221 (12.1) | 0.47** | − | − | 175 (23.7) | 1.87** | 1.55* (1.01–2.39) | 139 (13.4) | 0.97 | 0.86 (0.60–1.25) |
| Age (years) | |||||||||||||||||||
| 18–39 | 54 (36.0) | 1.00 | 1.00 | 82 (54.3) | 1.00 | 1.00 | 47 (31.3) | 1.00 | 1.00 | 34 (22.5) | 1.00 | 1.00 | 1.00 | 23 (22.3) | 1.00 | 1.00 | 20 (16.7) | 1.00 | 1.00 |
| 40–49 | 149 (46.4) | 1.54* | 1.35 (0.90–2.03) | 176 (53.8) | 0.98 | 0.86 (0.57–1.28) | 96 (29.3) | 0.91 | 0.82 (0.53–1.27) | 77 (23.7) | 1.07 | 0.83 (0.35–2.02) | 0.91 (0.51–1.62) | 73 (32.0) | 1.64 | 1.43 (0.82–2.51) | 51 (19.5) | 1.21 | 1.33 (0.74–2.38) |
| 50–59 | 263 (41.3) | 1.25 | 1.13 (0.77–1.65) | 279 (43.8) | 0.66* | 0.59** (0.40–0.85) | 135 (21.2) | 0.59** | 0.55** (0.36–0.83) | 133 (21.0) | 0.91 | 0.93 (0.43–1.99) | 0.61 (0.35–1.06) | 116 (28.9) | 1.41 | 1.27 (0.74–2.17) | 97 (19.5) | 1.21 | 1.31 (0.76–2.27) |
| 60–69 | 339 (27.8) | 0.68* | 0.63* (0.43–0.91) | 304 (25.0) | 0.28** | 0.25** (0.17–0.36) | 117 (9.6) | 0.23** | 0.22** (0.14–0.33) | 203 (17.0) | 0.71 | 0.72 (0.34–1.51) | 0.25** (0.14–0.44) | 32 (9.8) | 0.38** | 0.37** (0.20–0.69) | 66 (10.8) | 0.61 | 0.65 (0.37–1.15) |
| 70–79 | 172 (23.6) | 0.55** | 0.53** (0.36–0.78) | 125 (17.0) | 0.17** | 0.16** (0.11–0.24) | 48 (6.6) | 0.15** | 0.15** (0.09–0.24) | 69 (9.7) | 0.37** | 0.33** (0.15–0.72) | 0.04** (0.01–0.11) | 6 (3.6) | 0.13** | 0.12** (0.05–0.32) | 18 (5.6) | 0.30** | 0.30** (0.15–0.61) |
| 80+ | 51 (27.4) | 0.67 | 0.64 (0.39–1.03) | 31 (16.4) | 0.17** | 0.15** (0.09–0.26) | 10 (5.3) | 0.12** | 0.12** (0.06–0.25) | 13 (7.1) | 0.26** | 0.26** (0.10–0.69) | 0.06** (0.01–0.26) | 2 (4.0) | 0.14* | 0.14* (0.03–0.63) | 5 (6.0) | 0.32* | 0.35 (0.12–1.00) |
| Cancer diagnosis | |||||||||||||||||||
| Breast | 367 (39.5) | 1.00 | 1.00 | 338 (36.2) | 1.00 | 1.00 | 152 (16.3) | 1.00 | 1.00 | 111 (12.1) | 1.00 | − | 1.00 | 94 (23.9) | 1.00 | 1.00 | 62 (11.7) | 1.00 | 1.00 |
| Prostate | 96 (20.7) | 0.40** | 0.70* (0.50–0.99) | 89 (19.1) | 0.42** | 1.16 (0.80–1.66) | 30 (6.4) | 0.35** | 0.85 (0.51–1.43) | 159 (34.3) | 3.79** | 2.44** (1.67–3.56) | − | 15 (9.7) | 0.34** | 1.11 (0.52–2.36) | 22 (8.2) | 0.67 | 0.93 (0.49–1.78) |
| Colo-rectal | 142 (29.0) | 0.62** | 0.84 (0.65–1.10) | 109 (22.2) | 0.51* | 0.88 (0.66–1.18) | 50 (10.2) | 0.58** | 0.96 (0.66–1.41) | 68 (14.2) | 1.20 | 1.00 | 1.11 (0.65–1.89) | 31 (16.8) | 0.64 | 1.17 (0.69–1.98) | 32 (11.7) | 0.99 | 1.17 (0.70–1.96) |
| Gynecological | 69 (31.9) | 0.72* | 0.72* (0.52–0.99) | 79 (36.1) | 0.99 | 1.00 (0.72–1.38) | 43 (19.6) | 1.25 | 1.25 (0.85–1.85) | 41 (19.1) | 1.71** | − | 1.83** (1.21–2.77) | 26 (30.2) | 1.38 | 1.36 (0.80–2.32) | 22 (17.3) | 1.58 | 1.64 (0.96–2.82) |
| Malignant melanoma | 49 (22.4) | 0.44** | 0.48** (0.33–0.68) | 51 (23.2) | 0.53** | 0.52** (0.35–0.75) | 19 (8.6) | 0.49** | 0.43* (0.25–0.73) | 16 (7.3) | 0.57* | 0.34** (0.15–0.75) | 0.34** (0.16–0.75) | 8 (8.3) | 0.29** | 0.36* (0.16–0.80) | 13 (10.0) | 0.84 | 0.83 (0.43–1.62) |
| Lung | 71 (39.7) | 1.01 | 1.43* (1.01–2.04) | 70 (39.3) | 1.14 | 2.19** (1.52–3.16) | 28 (15.6) | 0.95 | 1.65* (1.03–2.66) | 27 (15.7) | 1.35 | 0.99 (0.53–1.84) | 1.53 (0.74–3.16) | 8 (15.7) | 0.59 | 1.09 (0.47–2.54) | 18 (17.1) | 1.56 | 2.00* (1.07–3.75) |
| Lymphoma | 35 (34.3) | 0.80 | 0.92 (0.59–1.44) | 49 (48.0) | 1.63* | 2.24 **(1.42–3.51) | 24 (23.8) | 1.60 | 1.90* (1.12–3.23) | 15 (15.0) | 1.28 | 0.87 (0.40–1.87) | 0.76 (0.29–2.02) | 9 (19.6) | 0.78 | 0.93 (0.41–2.10) | 11 (16.2) | 1.46 | 1.39 (0.67–2.91) |
| Head and neck | 32 (26.9) | 0.56** | 0.69 (0.43–1.09) | 39 (33.3) | 0.88 | 1.29 (0.82–2.04) | 15 (12.9) | 0.76 | 0.97 (0.52–1.80) | 12 (10.4) | 0.84 | 0.31** (0.13–0.72) | 1.49 (0.54–4.11) | 14 (25.5) | 1.09 | 1.57 (0.74–3.32) | 12 (15.0) | 1.33 | 1.20 (0.58–2.50) |
| Other | 167 (31.9) | 0.72** | 0.92 (0.70–1.20) | 173 (32.9) | 0.87 | 1.29 (0.98–1.70) | 92 (17.6) | 1.09 | 1.42* (1.01–2.02) | 80 (15.4) | 1.32 | 0.81 (0.52–1.25) | 1.07 (0.64–1.78) | 47 (22.5) | 0.93 | 1.38 (0.84–2.28) | 65 (20.8) | 1.99 | 2.03** (1.28–3.22) |
For each area (physical, emotional, family oriented, sexual, work-related, and financial) number, frequencies and crude and adjusted odds ratios (ORs) are shown with regard to sex, age, and cancer diagnosis
aAdjusted for sex, age group, and cancer diagnosis
bAdjusted for age group and cancer diagnosis
*p < 0.05
**p < 0.01